BNET Industries
Market Cap:$179.0M
Last Fiscal Year Sales:$350.3M
- Public
- US
Dow Jones Description
Generic & Private Label Prescription Drug Developer
Number of Employees 272
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection
-
Caraco Pharmaceutical Labs Launches Generic Of Acular Ophthalmic Solution - Quick Facts
-
Sun Pharma reports Q2 2009-10 financials
-
Caraco Pharmaceutical Laboratories, Ltd. CPD Closes Asset Purchase Agreement with Forest Laboratories, Inc. FRX to...
-
Caraco, Forest close settlement deal on Lexapro
-
Caraco BOD member resigns
-
Caraco Pharmaceutical Laboratories Announces Resignation Of Georges Ugeux From Board - Quick Facts
-
Caraco Pharmaceuticals CEO steps down
-
Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra...
-
Sun Pharma Profit Drops 67%
-
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Caraco Pharmaceutical Laboratories, Ltd., Announc
-
Caraco Pharmaceutical Laboratories, Ltd. CPD Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. FRX...
-
Sun Pharma Withdraws Sales Guidance on FDA Move
News & Analysis
Filter by
caraco pharmaceutical laboratories, ltd. - All News and Analysis
Caraco Pharma Awaits FDA Inspection in May
Mike Havrilla submits: I spoke with the investor relations representative for Caraco Pharma CPD earlier this week and received some clarity on the expected timeline for resolving the major overhang on the stock price related to the FDA warning letter over Form 483 concerns by the agency stemming from quality...
Interested in Small-Cap Generic Drugs? Keep an Eye on Caraco Pharma
Mike Havrilla submits: With shares of Hi-Tech Pharmacal HITK already up about 20% since I profiled the Company as a value play, investors interested in the small-cap generic drug industry should take a look at Caraco Pharma CPD at around 5 bucks. CPD reported results for its fiscal 3Q09 last...
Caraco Pharma Is a Compelling Value at This Price
Mike Havrilla submits: Caraco Pharma CPD offers a compelling value at its current price of $3.30 per share and I bought some shares today, as the stock has lost an astounding two-thirds of its market value in just the past month and over three-quarters of value in the past year.1.)...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Daniel Movens | CEO |
| Jitendra Doshi | CFO & COO |
| Robert Kurkiewicz | Senior Vice President, Technical |
| Gurpartap Singh | Vice President, Sales & Marketing |
| Daniel Barone | Director, Technical |
| Derrick Mann | Director, Regulatory Affairs |
| Jayesh Shah | Director, Commercial |
| Kaushikkumar Gandhi | Director, Manufacturing |
| Thomas Larkin | Director, Marketing |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Dilip Shanghvi | Chairman |
| Georges L. Ugeux | Board of Directors |
| John D. Crissman | Board of Directors |
| Madhava Reddy | Board of Directors |
| Shailesh Desai | Board of Directors |
| Sudhir Valia | Board of Directors |
| Timothy Manney | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | CEO | Current |
| Caraco Pharmaceutical Laboratories, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | CFO & COO | Current |
| Caraco Pharmaceutical Laboratories, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Senior Vice President, Technical | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Vice President, Sales & Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Director, Technical | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Director, Regulatory Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Director, Commercial | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Director, Manufacturing | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Director, Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Chairman | Current |
A lawyer and economist by training, Georges Ugeux has focused his entire 30 year career on the global dimensions of business, government and finance. He has a deep understanding of the cultural dimension of negotiations, networks and partnerships. Georges began his career in commercial banking at Societe Generale de Banque (now Fortis Bank), where he became the General Manager of the investment banking and trust division. He later served as Managing Director of Morgan Stanley's Mergers and Acquisitions department, as well as Group Finance Director at Societe Generale de Belgique, a Belgian conglomerate. In 1992, he became President and Managing Director of Kidder, Peabody Europe. He was also a member of the European Corporate Executive Council of General Electric. He was President of the European investment Fund, a public private partnership financing infrastructure and SME projects owned by the European Investment Bank, the European Community and 77 European banks. For seven years Georges immersed himself in the global equity markets by heading the International Group of the New York Stock Exchange, bringing over 300 non-US companies, valued at $ 2.7 trillion, to the US market. He is a frequent public speaker and educator on global issues (at the College of Europe in Bruges and Harvard Law School). Georges Ugeux holds a Doctorate in Law and is Licentiate in Economics from the Catholic University of Louvain. He chairs and sits on Boards of numerous transatlantic organizations.
| Organization | Position | Status |
|---|---|---|
| Galileo Global Advisors LLC | Chairman and CEO | Current |
| NYSE Group, Inc. | Group Executive Vice President | Current |
| The Essec USA | Current | |
| Belgian-American Chamber of Commerce | Board of Directors | Current |
| British-American Business Inc. | Director | Current |
| Caraco Pharmaceutical Laboratories, Ltd. | Board of Directors | Current |
| Morgan Stanley | Managing Director | Former |
| European Investment Bank | Former |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Caraco Pharmaceutical Laboratories, Ltd. | Board of Directors | Current |
Executive News
-
Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
-
Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in...
-
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Imitrex Tablets
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes

